 Co-Diagnostics NASDAQ:CODX Inc saw a healthy jump in year-over-year revenue driven by global sales of its Logix Smart COVID-19 tests, according to its latest financial results. The molecular diagnostics company clocked up 97.9 million in full-year 2021 revenue, an increase of 23.3 million over 2020 levels, and adjusted EBITDA of 52.1 million compared to 45.3 million in 2020. 